Guggenheim reiterated their buy rating on shares of Verve Therapeutics (NASDAQ:VERV - Free Report) in a report issued on Tuesday morning,Benzinga reports.
Several other research analysts have also recently weighed in on the stock. Royal Bank of Canada dropped their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. William Blair restated an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Verve Therapeutics in a report on Tuesday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Verve Therapeutics has a consensus rating of "Buy" and an average target price of $25.50.
Read Our Latest Report on VERV
Verve Therapeutics Stock Performance
Verve Therapeutics stock traded down $0.06 on Tuesday, reaching $5.22. The company's stock had a trading volume of 585,375 shares, compared to its average volume of 1,450,618. Verve Therapeutics has a twelve month low of $4.31 and a twelve month high of $13.24. The company has a market cap of $463.52 million, a price-to-earnings ratio of -2.12 and a beta of 1.77. The business's fifty day moving average price is $6.94 and its 200 day moving average price is $6.08.
Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.14. The business had revenue of $13.08 million for the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, equities analysts forecast that Verve Therapeutics will post -2.49 earnings per share for the current year.
Hedge Funds Weigh In On Verve Therapeutics
Several hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its position in shares of Verve Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock worth $101,000 after buying an additional 1,676 shares during the period. Rhumbline Advisers grew its holdings in Verve Therapeutics by 1.9% during the fourth quarter. Rhumbline Advisers now owns 111,203 shares of the company's stock valued at $627,000 after purchasing an additional 2,093 shares during the period. Arizona State Retirement System increased its stake in Verve Therapeutics by 15.8% in the fourth quarter. Arizona State Retirement System now owns 19,593 shares of the company's stock valued at $111,000 after purchasing an additional 2,669 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Verve Therapeutics by 5.8% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 50,230 shares of the company's stock valued at $313,000 after purchasing an additional 2,742 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Verve Therapeutics by 5.7% in the fourth quarter. Invesco Ltd. now owns 57,140 shares of the company's stock worth $322,000 after purchasing an additional 3,080 shares during the period. Institutional investors and hedge funds own 97.11% of the company's stock.
Verve Therapeutics Company Profile
(
Get Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Recommended Stories
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
